Helpful or Harmful: Using AI in the Rare Disease Space

The Rare Disease Summit connects key stakeholders to drive therapeutic progress, propel commercial strategies, and inspire impactful advocacy.

OSIC Executive Director Elizabeth Estes, Melissa Leichter of Novo Nordisk, and Panna Sharma of Lantern Pharma Inc. discussed the potential of using AI and machine learning to treat rare disease in the session, “Helpful or Harmful: Using AI in the Rare Disease Space.”